Beijing Tong Ren Tang Chinese Medicine : RETIREMENT OF EXECUTIVE DIRECTOR, CHIEF EXECTIVE OFFICER AND MEMBER OF BOARD COMMITTEE AND RE-DESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF EXECTIVE OFFICER AND MEMBER OF BOARD COMMITTEE

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 北京同仁堂國藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3613)

RETIREMENT OF EXECUTIVE DIRECTOR, CHIEF EXECTIVE OFFICER

AND MEMBER OF BOARD COMMITTEE

AND

RE-DESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF

CHIEF EXECTIVE OFFICER AND MEMBER OF BOARD COMMITTEE

The Board announces that with effect from 11 March 2021:

(i) Mr. Zhang Huan Ping has retired as an Executive Director, the Chief Executive Officer and a member of the Competition Executive Committee; and

(ii)Mr. Chen Fei, a Non-Executive Director, has been re-designated as an Executive Director and appointed as the Chief Executive Officer and a member of the Competition Executive Committee.

RETIREMENT OF EXECUTIVE DIRECTOR, CHIEF EXECTIVE OFFICER AND MEMBER OF BOARD COMMITTEE

The board of directors (the "Board") of Beijing Tong Ren Tang Chinese Medicine Company Limited (the "Company") hereby announces that Mr. Zhang Huan Ping ("Mr. Zhang") has retired as an executive director of the Company ("Executive Director"), the chief executive officer of the Company (the "Chief Executive Officer") and a member of the Competition Executive Committee of the Company as Mr. Zhang has passed the retirement age with effect from 11 March 2021.

Mr. Zhang has confirmed to the Board that he has no disagreement with the Board and there are no other matters that need to be brought to the attention of the shareholders of the Company in relation to his retirement.

During his tenure of service at the Company, Mr. Zhang faithfully performed his duties and contributed to the Company's development and enhanced the Company's sustainability. The Board would like to express its sincere gratitude to Mr. Zhang for his valuable contribution.

RE-DESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF EXECTIVE OFFICER AND MEMBER OF BOARD COMMITTEE

The Board is pleased to further announce that Mr. Chen Fei ("Mr. Chen"), currently a non-executive director of the Company ("Non-Executive Director"), has been re-designated as an Executive Director, and appointed as the Chief Executive Officer and a member of the Competition Executive Committee of the Company with effect from 11 March 2021.

The biographical details of Mr. Chen are set out as follows:

Chen Fei, aged 50, has been appointed as a Non-Executive Director since 24 March 2020. Mr. Chen joined Beijing Tong Ren Tang Group in August 1994 and formerly served as the manager and deputy manager of Operational Management Department of China Beijing Tong Ren Tang Group Co., Ltd ("Tong Ren Tang Holdings") which is the ultimate holding company of the Company, the deputy manager of Pricing Department of Tong Ren Tang Holdings, the deputy manager of Economic Operation Department of Tong Ren Tang Holdings and the general manager of Beijing Tong Ren Tang (Thailand) Co., Ltd.. Mr. Chen obtained a bachelor's degree in Chinese medicine from School of Chinese Medicine of Beijing Union University in August 1994.

As at the date of this announcement, Mr. Chen has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Mr. Chen does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")) of the Company nor does he hold any other position with the Company or any of its subsidiaries.

LENGTH OF SERVICE AND DIRECTOR'S EMOLUMENTS

A service agreement (the "Agreement") was entered into between the Company and Mr. Chen on 11 March 2021 for a period of three years. Pursuant to the Agreement, Mr. Chen will not receive any director's fee as an Executive Director. For the year ended 31 December 2020, Mr. Chen did not receive any Director's fee as a Non-Executive Director. The emolument of Mr. Chen as the Chief Executive Officer shall be determined by the Board with reference to his duties and responsibilities with the Company and the Company's remuneration policy.

INTERESTS IN SHARES

As at the date of this announcement, Mr. Chen does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

OTHER INFORMATION AND MATTERS THAT NEED TO BE DISCLOSED OR BROUGHT TO THE ATTENTION OF SHAREHOLDERS OF THE COMPANY

Save as the above disclosed, Mr. Chen has confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the shareholders of the Company in connection with the aforesaid appointment.

By order of the Board

Beijing Tong Ren Tang

Chinese Medicine Company Limited

Ding Yong Ling

Chairman

Hong Kong, 11 March 2021

As at the date of this announcement, the composition of the Board is as follows:

Executive Director:	Independent non-executive Director:
Ms. Ding Yong Ling	Mr. Tsang Yok Sing, Jasper
Mr. Zhang Huan Ping (retired on 11 March 2021)	Mr. Zhao Zhong Zhen
Mr. Chen Fei (redesignated on 11 March 2021)	Mr. Chan Ngai Chi
Ms. Lin Man